Skip to main content

Market Overview

AstraZeneca's Tagrisso Scores Approval In China For Early Lung Cancer

Share:
AstraZeneca's Tagrisso Scores Approval In China For Early Lung Cancer
  • AstraZeneca Plc (NASDAQ: AZN) said that China’s health regulator had expanded the use of Tagrisso in patients with a type of lung cancer when diagnosed at an early stage.
  • China’s National Medical Products Administration (NMPA) approved Tagrisso as adjuvant therapy for early-stage lung cancer patients who have a mutation of the EGFR gene.
  • The drug is now approved to treat early-stage lung cancer in more than a dozen countries, including, most recently, in the United States.
  • The Chinese approval was based on positive results from a late-stage trial that showed Tagrisso cut the risk of disease recurrence or death by 83%.
  • Price Action: AZN shares are up 1.46% at $49.91 in premarket trading on the last check Wednesday.
 

Related Articles (AZN)

View Comments and Join the Discussion!

Posted-In: Briefs lung cancer National Medical Products AdministrationBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com